Tuesday March 10Tuesday, 10 March 2026 - PT (Pacific Time, GMT-08:00)

• Running multiple cycles on smaller chromatography columns in dual column mode, as well as connecting multiple unit operations together in continuous fashion is a strategy to enable processing of the additional mass entering the downstream process from intensified fed batch bioreactors.
• Continuous multi-cycle operation ensures that the processing time meets or even exceeds that of standard batch methods, enabling facilities to meet their required run rates without compromising purity or yield.
• The reduction in chromatography resin volume and buffer usage enables a reduced facility footprint and lower cost of goods of manufacturing, while also improving sustainability initiatives

• Continuous downstream processing based on capture via target precipitation and polish via flowthrough chromatography offers a low cost-of-goods, low process mass index, and low complexity pathway to monoclonal antibody manufacture.
• Yield, purity, and throughput metrics for the precipitation-based process compare favorably to those for platform Protein A downstream processes.
• Capture via precipitation is broadly applicable to monoclonal antibodies and antibody-like therapeutics.
• The process development workflow in terms of selection of precipitant conditions and polishing resins is straightforward.

This panel will move beyond the “which is better” debate to address how leading companies evaluate and select the right upstream strategy across their portfolios. Experts will share case studies and business studies on decision-making frameworks, considering factors such as molecule type, clinical phase, cost of goods, regulatory expectations, facility readiness, and long-term scalability. Discussions will also explore the role of modeling, digital twins, and AI-driven analytics in simulating productivity and risk trade-offs between fed-batch, intensified, and fully continuous processes.